Risperidone Cross-over design query [Design Issues]

posted by ElMaestro  – Denmark, 2008-12-25 08:41 (6387 d 18:01 ago) – Posting: # 2977
Views: 5,765

Since you are comparing fomulations and not metabolisms, I think it would be acceptable (in a purely scientific manner) to simply write in the protocol that poor metabolisers are excluded; this involves testing for it at the time of recruitment.
Then it becomes easier to time the blood sampling and shorten the study/period duration.

EM.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
135 visitors (0 registered, 135 guests [including 31 identified bots]).
Forum time: 03:42 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5